Randomized trial investigates pharmacokinetics and safety of an anti-PACAP monoclonal antibody for migraine prevention, indicating potential therapeutic use.
To investigate the pharmacokinetics (PK) and safety of Lu AG09222 using data from three phase 1 clinical trials.
No takes yet. Share an insight, caveat, or question.
Ashina et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: